Posts

Alnylam Cuts Amvuttra Sales Guidance as Second-Line Demand Normalizes, Hitting Stock

on

AZ, Ionis Shares Tumble on ATTR‑CM Trial Flop, But Analyst Flags Over‑Reaction Explained

on

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

on

Alnylam and Tenaya Partner in $1.13B Cardiovascular Gene Target Collaboration

on

Tenaya Therapeutics Partners with Alnylam in $1.13B Cardiovascular Gene Target Collaboration

on

Roche and Alnylam Push Zilebesiran into Phase III Trial Despite Mixed Phase II Hypertension Data

on

Regeneron Reports Phase 3 Success for Cemdisiran in Rare Disease Generalized Myasthenia Gravis

on

Alnylam Surpasses $50B Market Cap as Amvuttra Heart Disease Launch Impresses Wall Street

on